Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)

Tipranks - Tipranks - Thu Apr 16, 3:50AM CDT

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences yesterday and set a price target of $165.00. The company’s shares closed yesterday at $140.45.

Claim 30% Off TipRanks

Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Eli Lilly & Co. According to TipRanks, Bansal has an average return of 9.5% and a 56.87% success rate on recommended stocks.

In addition to Wells Fargo, Gilead Sciences also received a Buy from Scotiabank’s Louise Chen in a report issued on April 13. However, on April 7, Goldman Sachs maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

See the top stocks recommended by analysts >>

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.93 billion and a net profit of $2.18 billion. In comparison, last year the company earned a revenue of $7.57 billion and had a net profit of $1.78 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).